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Toxoplasma gondii (T. gondii), cytomegalovirus (CMV), and
Listeria monocytogenes (L. monocytogenes) can all nega-
tively affect pregnancy outcomes. Preconception counsel-
ing about such effects can reduce the risks posed by these
pathogens. Informing women of childbearing age about these
pathogens and how to prevent their negative effects can
help women make informed decisions about prevention. This
brief summarizes some basic information about these infec-
tions and provides some web sites and articles for further
information about how to prevent them within the context of
preconception care.
Toxoplasmosis is a disease caused by Toxoplasma gondii
(T. gondii), a protozoan parasite mainly transmitted to hu-
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mans via three routes: a) ingestion of raw or undercooked
contaminated meat; b) exposure to T. gondii oocysts (a form
of the organism passed in cat feces), through cat litter or
soil (e.g., from gardening or unwashed fruits or vegetables),
or contaminated water; and c) congenital in which maternal
infection is passed transplacentally via blood to the fetus
[1]. Congenital infection leads to stillbirth and severe neu-
rological illness in some instances, although the majority
of infected newborns are asymptomatic at birth and some
develop sequelae such as mental retardation, blindness, and
epilepsy later in life [2]. Extrapolation from regional studies
suggests that ∼400–4,000 cases of congenital toxoplasmosis
occur each year in the United States [2].
Adults with normal immune function who are infected
with T. gondii are usually asymptomatic or have self-limited
symptoms (e.g., fever, malaise, and lymphadenopathy) [1].
Once infected, these individuals usually develop an immune
response against toxoplasmosis [3, 4]. A recent study based
on the National Health and Nutrition Survey conducted from
1988–1994 (NHANES III) reported that, among women aged
15–44 years, seroprevalence of T. gondii antibodies was 15%,
suggesting that ∼85% of women of childbearing age are
susceptible to T. gondii infection [5].
Three principal interventions are presently used to reduce
morbidity and mortality from congenital toxoplasmosis: a)
education about how to prevent infection (especially during
pregnancy); b) prenatal and newborn screening to identify
and treat congenital infection; and c) animal rearing and
production methods designed to reduce T. gondii contami-
nation of meat. Of the three, education about how to prevent
infection is applicable to adolescents and women in the pre-
conception period. Education programs during pregnancy
have been associated with improved knowledge and behav-
ior and a reduction in infection rates [6–9]. Toxoplasma in-
fection can be prevented by one or more of the following:
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a) cooking meat to a sufficient temperature to kill Toxo-
plasma; b) peeling or thoroughly washing fruits and vegeta-
bles before eating; c) cleaning cooking surfaces and utensils
after they have contacted raw meat, poultry, or unwashed
fruits or vegetables; d) pregnant women avoiding changing
cat litter or using gloves, then washing hands thoroughly; and
e) not feeding raw or undercooked meat to cats and keeping
cats inside to prevent acquisition of Toxoplasma by eating
infected prey [2].
Although prenatal and newborn screening programs have
been evaluated, they are controversial because of the lack
of proven efficacy of treatment, side effects of treatment,
and potential complications of invasive procedures such as
amniocentesis to evaluate fetal infection [10–23]. Animal
rearing and production methods to reduce T. gondii con-
tamination of meat are effective and have been associated
with a reduction in the prevalence of T. gondii in impor-
tant meat sources such as pork [24]; however the need for
improvement in producers’ knowledge and production prac-
tices is acknowledged [25]. Education about toxoplasmosis
is an important component of preconception care that can be
integrated with information about other diseases that affect
women.
Human cytomegalovirus (CMV) is the largest DNA virus
belonging to the herpesvirus family. Humans are the only
reservoirs for the human herpesviruses, and they can trans-
mit these agents through direct contact with infected blood,
tissues, bodily fluids, feces, and fomites [26]. A pregnant
woman infected with CMV can transmit this virus to her
unborn fetus, which can cause damage to the central nervous
system, hematopoietic system, kidneys, endocrine glands,
gastrointestinal tract, lungs, and liver. Long-term sequelae
include cerebral palsy, mental retardation, and hearing loss
[26, 27]. The birth prevalence rate of congenital CMV infec-
tion varies between ∼0.6–1.5% [28–30] in the United States,
making it the most commonly transmitted virus in utero [26,
31] and a major cause of cerebral palsy, mental retardation,
and hearing loss among children [27, 31].
CMV infects almost all humans at some point in their
lives. Adults with normal immune function infected with
CMV are usually asymptomatic or might experience mild
flu-like symptoms, or even mononucleosis with symptoms
such as malaise, persistent fever, myalgia, and cervical lym-
padenopathy [26, 31]. Once a human is infected, the virus
passes into a latent state [26]. Although the virus can be reac-
tivated, it is usually kept under control, because adults with
normal immune function usually retain lifelong immunity
against CMV.
Primary CMV infection of women during pregnancy
or periconceptionally results in transmission to the fetus
transplacentally in ∼30–40% of maternal infections [26, 32–
34]. Preexisting maternal immunity strongly reduces the risk
of transmission to the fetus [34]. However, approximately
10–15% of newborns with congenital CMV will be symp-
tomatic and from ∼6–25% of those born without symptoms
will develop late sequelae [35].
The most common means for women to be infected with
CMV is by exposure to toddlers who shed large amounts of
the virus in their saliva and urine for many months follow-
ing their first (usually asymptomatic) infection [26, 36–40].
Daycare providers and pregnant women who have a tod-
dler of their own are at high risk for infection [41–46].
Sexual transmission, blood transfusion, and organ trans-
plantation are other means by which CMV is transmitted
[26]. It is important to counsel all women about safe sex
practices.
Currently, there are no vaccines available for preventing
CMV infection, although some promising advances have
been made [47, 48]. It is, therefore, extremely important to
provide women of childbearing age with information about
how they can prevent CMV infection before conception.
The most effective means for preventing CMV infection is
handwashing [26, 49–53]. Education about careful hygiene
and frequent handwashing, especially after contact with the
saliva and urine of young children, and careful disposal
of diapers, tissues, and other contaminated items can re-
duce the transmission of CMV. Avoiding sharing drinking
glasses and eating utensils with young children can also pre-
vent transmission. This is especially true for women who
work in daycare settings and for those who are pregnant
[26, 49–54].
As some studies suggest that CMV infection prior to con-
ception can result in congenital CMV infection [26, 30, 55],
counseling all women of childbearing age about how to pre-
vent transmission preconceptionally could significantly re-
duce the incidence of congenital CMV infection.
Listeriosis is an invasive foodborne infection caused by
the motile, gram-positive bacterium Listeria monocytogenes
(L. monocytogenes). The disease affects primarily pregnant
women, newborns, and adults with weakened immune sys-
tems [56]. Maternal infection during pregnancy is usually
a self-limited, nonspecific acute febrile illness of the third
trimester. In contrast to the maternal illness, fetal and neona-
tal infection is severe and frequently fatal. Infection in the
fetus and newborn occurs by transplacental transmission or
possibly from exposure to L. monocytogenes in the perina-
tal period. The effects of intrauterine infection on the fetus
and neonate include preterm labor, amnionitis, spontaneous
abortion, still birth, and early-onset of the neonatal sepsis
syndrome, evident at birth or shortly thereafter. Late-onset
neonatal disease is likely due to infection at or around the
time of birth, and presents as meningitis at one to several
weeks of age [57].
Listeriosis is a rare disease; the incidence rate in 10 states
participating in the Foodborne Diseases Active Surveillance
Network (FoodNet) was 2.7 cases per 1,000,000 population
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in the year 2004 [58]. However, the incidence rate in suscep-
tible subgroups is much higher. The rate among neonates
younger than 28 days of age in FoodNet sites was 52.8
per 100,000 population in the year 2000 (CDC unpublished
data). More importantly, listeriosis has a very high case fa-
tality rate (20–30% in neonates) and is responsible for an
estimated 500 deaths each year in the United States [59].
The food items implicated in outbreaks of listeriosis in-
clude ready-to-eat meats, such as turkey delicatessen meat
[60], meat pate´ [61], pork tongue in jelly [62], hot dogs
[63], and dairy products made from unpasteurized milk, in
particular fresh soft cheeses [64].
Primary prevention for listeriosis focuses on improve-
ments in food processing and on consumer education. Sub-
stantial efforts by the food industry and food regulatory agen-
cies have been directed toward reducing the likelihood that
high risk foods will be contaminated with L. monocytogenes
[65]. Despite this, pregnant women, immunocompromised
persons, and the elderly should be advised to avoid pate´,
fresh soft cheeses made from unpasteurized milk and to cook
ready-to-eat foods such as hotdogs, delicatessen meats, and
left over foods until steaming [66]. Information regarding
these foods at high risk of contamination with Listeria can
be incorporated into preconception care dietary recommen-
dations.
For more information
CDC web sites
Toxoplasmosis: http://www.cdc.gov/ncidod/dpd/parasites/
toxoplasmosis/default.htm
CMV: http://www.cdc.gov/cmv
Listeria: http://www.cdc.gov/ncidod/dbmd/diseaseinfo/
listeriosis g.htm
Publications for practitioners
Disclaimer: These references are included for information
only. CDC has no control over the information in these ar-
ticles. Views and opinions of these organizations are not
necessarily those of CDC, the Department of Health and
Human Services (HHS), or the U.S. Public Health Service
(PHS).
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